|
gptkbp:instanceOf
|
gptkb:antiretroviral_therapy
gptkb:protease_inhibitor
|
|
gptkbp:administeredBy
|
oral
intravenous
|
|
gptkbp:alsoKnownAs
|
gptkb:AZT
gptkb:Retrovir
|
|
gptkbp:approvalYear
|
1987
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AF01
|
|
gptkbp:bioavailability
|
60–70% (oral)
|
|
gptkbp:CASNumber
|
30516-87-1
|
|
gptkbp:category
|
gptkb:antiviral_drug
gptkb:World_Health_Organization_essential_medicine
|
|
gptkbp:chemicalFormula
|
C10H13N5O4
|
|
gptkbp:combinationTherapy
|
often combined with lamivudine
|
|
gptkbp:contraindication
|
hypersensitivity to zidovudine
|
|
gptkbp:developedBy
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discoveredBy
|
gptkb:Jerome_Horwitz
|
|
gptkbp:drugClass
|
antiviral
|
|
gptkbp:eliminationHalfLife
|
1 hour
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1964
|
|
gptkbp:KEGGID
|
gptkb:D00351
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reverse transcriptase
|
|
gptkbp:meltingPoint
|
125–127 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
267.24 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
used to prevent HIV transmission to fetus
|
|
gptkbp:proteinBinding
|
34–38%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL458
32598
35370
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
gptkb:muscular_dystrophy
nausea
headache
neutropenia
|
|
gptkbp:solubility
|
water soluble
|
|
gptkbp:UNII
|
4B9XT59T7S
|
|
gptkbp:usedFor
|
HIV infection
prevention of mother-to-child transmission of HIV
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:NRTIs
gptkb:AZT
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
zidovudine
|